{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,20]],"date-time":"2026-09-20T23:48:52Z","timestamp":1789948132273,"version":"4.0.1"},"reference-count":21,"publisher":"BMJ","content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["BMJ Case Reports"],"accepted":{"date-parts":[[2018,2,25]]},"abstract":"<jats:p>A 70-year-old man presented with left loin pain without urinary symptoms. Initial investigations with CT showed enlarged para-aortic, mediastinal lymph nodes, right-side renal mass and enlarged prostate. A prostatic-specific antigen (PSA) was alarmingly high at 4750\u2009\u03bcg\/L (normal &lt;4.0\u2009\u03bcg\/L). Further investigations included positron emission tomography (PET); both prostate-specific membrane antigen and 18-fluorodeoxyglucose as well as bone scan and bone marrow examination confirmed dual malignancies with B-cell non-Hodgkin\u2019s lymphoma (B-NHL) and wide spread metastatic prostatic adenocarcinoma (PA) to the skull, spine, pelvis, liver and lungs. The patient was treated with six cycles of rituximab, etoposide, prednisone, vincristine, cyclophosphamide and doxorubicin(R-EPOCH) containing regimen for B-NHL and goserelin hormonal therapy for PA. Restaging with PET scans thereafter showed complete remission of NHL with disappearance of his metastatic PA and normalisation of PSA levels. R-EPOCH regimen and antiandrogen therapy resulted in a good outcome and remission of both malignancies.<\/jats:p>","DOI":"10.1136\/bcr-2017-223637","type":"journal-article","created":{"date-parts":[[2018,3,16]],"date-time":"2018-03-16T11:31:16Z","timestamp":1521199876000},"page":"bcr-2017-223637","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":6,"title":["Successful treatment of concomitant metastatic prostate cancer and B-cell non-Hodgkin\u2019s lymphoma with R-EPOCH chemotherapy regimen and antiandrogen therapy"],"prefix":"10.1136","volume":"2018","author":[{"given":"Fayez","family":"Hanna","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ajay","family":"Prakash","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ebony","family":"Allan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2399-3311","authenticated-orcid":false,"given":"Alhossain A","family":"Khalafallah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2018,3,16]]},"reference":[{"key":"2025042703080204000_2018.mar15_3.bcr-2017-223637.1","doi-asserted-by":"crossref","first-page":"602","DOI":"10.1016\/j.aller.2017.01.006","article-title":"Epidemiology and pathophysiology of malignancy in common variable immunodeficiency?","volume":"45","author":"Tak Manesh","year":"2017","journal-title":"Allergol Immunopathol"},{"key":"2025042703080204000_2018.mar15_3.bcr-2017-223637.2","doi-asserted-by":"publisher","DOI":"10.1007\/s00277-015-2543-4"},{"key":"2025042703080204000_2018.mar15_3.bcr-2017-223637.3","doi-asserted-by":"crossref","DOI":"10.1200\/jco.2015.33.15_suppl.e16101","article-title":"Concurrence of prostatic adenocarcinoma and lymphoma: clinical and pathological characteristics\u2013Single institutional experience","volume":"33","author":"Dhillon","year":"2015","journal-title":"Journal of Clinical Oncology"},{"key":"2025042703080204000_2018.mar15_3.bcr-2017-223637.4","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2012-07-440073"},{"key":"2025042703080204000_2018.mar15_3.bcr-2017-223637.5","first-page":"10","article-title":"Targeting bone metastases in metastatic castration-resistant prostate ancer","volume":"11","author":"Joelle","year":"2016","journal-title":"Clinical Medicine Insights: Oncology"},{"key":"2025042703080204000_2018.mar15_3.bcr-2017-223637.6","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1159\/000457117","article-title":"Primary extranodal diffuse large b-cell lymphoma of the prostate: a case report","volume":"10","author":"Ezekwudo","year":"2017","journal-title":"Case Rep Oncol"},{"key":"2025042703080204000_2018.mar15_3.bcr-2017-223637.7","doi-asserted-by":"crossref","first-page":"880","DOI":"10.1111\/bju.13483","article-title":"Co-introduction of a steroid with docetaxel chemotherapy for metastatic castration-resistant prostate cancer affects PSA flare","volume":"118","author":"Shiota","year":"2016","journal-title":"BJU Int"},{"key":"2025042703080204000_2018.mar15_3.bcr-2017-223637.8","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12889-017-4439-9","article-title":"Benefits and harms of prostate cancer screening - predictions of the ONCOTYROL prostate cancer outcome and policy model","volume":"17","author":"M\u00fchlberger","year":"2017","journal-title":"BMC Public Health"},{"key":"2025042703080204000_2018.mar15_3.bcr-2017-223637.9","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1159\/000277743","article-title":"Metastatic prostate cancer in an asymptomatic patient with an initial prostate-specific antigen (PSA) serum concentration of 21,380 ng\/ml","volume":"33","author":"Persec","year":"2010","journal-title":"Onkologie"},{"key":"2025042703080204000_2018.mar15_3.bcr-2017-223637.10","doi-asserted-by":"crossref","first-page":"317","DOI":"10.36076\/ppj.2001\/4\/317","article-title":"Metastatic prostate cancer to the spine and a PSA of 5666: a case report","volume":"4","author":"Slipman","year":"2001","journal-title":"Pain Physician"},{"key":"2025042703080204000_2018.mar15_3.bcr-2017-223637.11","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1515\/amma-2016-0044","article-title":"Metastatic prostate cancer with highest reported PSA level","volume":"62","author":"Orsolya","year":"2016","journal-title":"Acta Medica Marisiensis"},{"key":"2025042703080204000_2018.mar15_3.bcr-2017-223637.12","doi-asserted-by":"crossref","first-page":"1187","DOI":"10.3892\/ol.2014.2829","article-title":"Primary non-Hodgkin\u2019s lymphoma of the prostate with intractable hematuria: a case report and review of the literature","volume":"9","author":"Hu","year":"2015","journal-title":"Oncol Lett"},{"key":"2025042703080204000_2018.mar15_3.bcr-2017-223637.13","doi-asserted-by":"crossref","first-page":"928","DOI":"10.1182\/blood.V54.4.928.928","article-title":"Serum lactic dehydrogenase as a prognostic tool for non-Hodgkin lymphomas","volume":"54","author":"Ferraris","year":"1979","journal-title":"Blood"},{"key":"2025042703080204000_2018.mar15_3.bcr-2017-223637.14","first-page":"621","article-title":"[Primary malignant lymphoma of the prostate: report of a case achieving complete response to combination chemotherapy and review of 22 Japanese cases]","volume":"94","author":"Fukutani","year":"2003","journal-title":"Nihon Hinyokika Gakkai Zasshi"},{"key":"2025042703080204000_2018.mar15_3.bcr-2017-223637.15","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1155\/2014\/247286","article-title":"Coexisting mantle cell lymphoma and prostate adenocarcinoma","volume":"2014","author":"Rajput","year":"2014","journal-title":"Case Rep Med"},{"key":"2025042703080204000_2018.mar15_3.bcr-2017-223637.16","doi-asserted-by":"crossref","DOI":"10.1186\/1471-2407-14-613","article-title":"Incidental advanced-stage Hodgkin lymphoma diagnosed at the time of radical prostatectomy for prostatic cancer: a case report and review of literature","volume":"14","author":"Di Meglio","year":"2014","journal-title":"BMC Cancer"},{"key":"2025042703080204000_2018.mar15_3.bcr-2017-223637.17","doi-asserted-by":"publisher","DOI":"10.1097\/01.pas.0000153122.65138.b1"},{"key":"2025042703080204000_2018.mar15_3.bcr-2017-223637.18","doi-asserted-by":"crossref","first-page":"977","DOI":"10.4103\/0973-1482.176122","article-title":"Primary diffuse large B-cell lymphoma of the prostate: a report of two cases with diagnostic considerations","volume":"11","author":"Kakkar","year":"2015","journal-title":"J Cancer Res Ther"},{"key":"2025042703080204000_2018.mar15_3.bcr-2017-223637.19","doi-asserted-by":"crossref","unstructured":"Jelrik Oosterheert J , Budel M , Vos, P L , et al . High levels of serum prostate-specific antigen due to PSA producing follicular non-Hodgkin\u2019s lymphoma, 2007.","DOI":"10.1111\/j.1600-0609.2007.00883.x"},{"key":"2025042703080204000_2018.mar15_3.bcr-2017-223637.20","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1016\/S0090-4295(99)80099-5","article-title":"False-positive serum prostate-specific antigen values in a patient with non-Hodgkin lymphoma of the kidney","volume":"45","author":"Djavan","year":"1995","journal-title":"Urology"},{"key":"2025042703080204000_2018.mar15_3.bcr-2017-223637.21","doi-asserted-by":"crossref","DOI":"10.4084\/mjhid.2011.018","article-title":"High serum erythropoietin and ferritin levels in conjunction with anemia response in malignant lymphoma","volume":"3","author":"Omari","year":"2011","journal-title":"Mediterr J Hematol Infect Dis"}],"container-title":["BMJ Case Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bcr-2017-223637","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,27]],"date-time":"2025-04-27T10:08:11Z","timestamp":1745748491000},"score":1,"resource":{"primary":{"URL":"https:\/\/casereports.bmj.com\/lookup\/doi\/10.1136\/bcr-2017-223637"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,3,16]]},"references-count":21,"alternative-id":["10.1136\/bcr-2017-223637"],"URL":"https:\/\/doi.org\/10.1136\/bcr-2017-223637","relation":{},"ISSN":["1757-790X"],"issn-type":[{"value":"1757-790X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,3,16]]}}}